Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

Abstract: The present invention is directed to 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the enteropeptidase enzyme.

Abstract: Described herein are various technologies pertaining to integrating account identifier (e.g., card provider(s)) into a digitization system, for example, without requiring changes to a client application on a user device (e.g., smart phone). An extensible account identifier abstraction system is provided that stores data according to a unified data model and is accessible to the user device via unified interface(s). The extensible abstraction system includes one or more plugin modules/provider relay plugin(s) that convert call(s) to the unified interface(s) and data stored according to the unified data model into provider-specific call(s) with data formatted according to a provider-specific schema.

Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Abstract: The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g., enucleated erythroid cells and platelets), that are engineered to include exogenous-antigen presenting polypeptides comprising either HLA-E or HLA-G polypeptides, which may be used to activate or suppress certain immune cells.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: Described herein are various technologies pertaining to integrating account identifier (e.g., card provider(s)) into a digitization system, for example, without requiring changes to a client application on a user device (e.g., smart phone). An extensible account identifier abstraction system is provided that stores data according to a unified data model and is accessible to the user device via unified interface(s). The extensible abstraction system includes one or more plugin modules/provider relay plugin(s) that convert call(s) to the unified interface(s) and data stored according to the unified data model into provider-specific call(s) with data formatted according to a provider-specific schema.

Abstract: Described herein are various technologies pertaining to integrating account identifier (e.g., card provider(s)) into a digitization system, for example, without requiring changes to a client application on a user device (e.g., smart phone). An extensible account identifier abstraction system is provided that stores data according to a unified data model and is accessible to the user device via unified interface(s). The extensible abstraction system includes one or more plugin modules/provider relay plugin(s) that convert call(s) to the unified interface(s) and data stored according to the unified data model into provider-specific call(s) with data formatted according to a provider-specific schema.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.

Abstract: Described herein are various technologies pertaining to integrating account identifier (e.g., card provider(s)) into a digitization system, for example, without requiring changes to a client application on a user device (e.g., smart phone). An extensible account identifier abstraction system is provided that stores data according to a unified data model and is accessible to the user device via unified interface(s). The extensible abstraction system includes one or more plugin modules/provider relay plugin(s) that convert call(s) to the unified interface(s) and data stored according to the unified data model into provider-specific call(s) with data formatted according to a provider-specific schema.